Shares of Novo Nordisk surged 10% following positive early-stage results for its once weekly amycretin obesity drug, which led to a 22% weight reduction in obese and overweight patients compared to a 2.0% weight gain in the placebo group. The trial showed promising results for amycretin, a treatment that targets the same gut and pancreas hormones as Novo Nordisk’s flagship obesity drug Wegovy and diabetes treatment Ozempic. Novo Nordisk is also developing an amycretin obesity pill, with early-stage trials demonstrating a 13.1% weight loss after 12 weeks and mild-to-moderate side effects.
Full Article
US judge finds probable cause to hold Trump officials in contempt over alien act deportations | Trump administration
A federal judge determined on Wednesday that there is probable cause to hold Trump officials in contempt for breaching a temporary injunction that prohibited the application of the Alien Enemies Act to deport suspected Venezuelan gang members. This ruling highlights ongoing legal challenges surrounding the treatment of foreign nationals under wartime powers. Further details regarding the implications of this decision and the actions of the officials involved are expected to be released shortly. Full Article
Read more